George Tidmarsh, director of the FDA's Center for Drug Evaluation and Research (CDER), has been appointed as the acting director of the Center for Biologics Evaluation and Research (CBER) following the abrupt resignation of Vinay Prasad. Scott Steele and Brittany Goldberg will serve as deputy directors at CBER during this transition. Prasad's departure has been linked to controversies surrounding Sarepta Therapeutics and its drug, which has faced criticism for its efficacy and safety after the deaths of two patients. Sarepta reportedly engaged the lobbying firm Michael Best Strategies and political influencer Chris LaCivita, who is associated with Laura Loomer, preceding a wave of media attacks on Prasad. Critics have accused Sarepta of manufacturing patient advocacy and promoting ineffective treatments, while Prasad was seen as a regulator committed to anti-corruption and scientific integrity. His exit highlights tensions between regulatory oversight and pharmaceutical company interests within the FDA.